Skip to content
Menu

Enliven Therapeutics, Inc. ELVN

Full chart Compare
Set alert

Price alert · ELVN

All alert types
46.85 USD -0.77 (-1.62%)

Regular-session close

46.85 0.00 0.00%

After hours · Nov 17, 4:00 PM ET

46.05 Day range 47.75
14.79 52-week range 62.32
YTD
+204.22%
1 year
+115.30%
Market cap
3.45B
EPS (ttm)
-1.69
Shares out
73.60M
Forward P/E
-23.49
YTD return
+204.22%
1-year return
+115.30%
50-day average
46.20
200-day average
43.94
Enterprise value
2.62B
Price / book
3.93
Volume
652.27K
Avg volume
1.35M
Open
47.61
Previous close
47.62
Day's range
46.05 – 47.75
52-week range
14.79 – 62.32
Beta
0.36
Analysts
Strong Buy
Price target
74.33 (+58.7%)
Earnings date
Mar 2, 2027

 

No chart data for this range yet.

Key statistics

Free cash flow
-43.62M
Total cash
884.35M
Total debt
1.31M
Return on equity
-16.77%
Short % of float
20.11%

Fundamental scorecard

6 of 25 checks passed on ELVN’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ELVN Revenue — quarterly 0
ELVN Net income — quarterly -27.70M
ELVN EPS — quarterly -0.36

Earnings

ELVN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 2, 2027Dec 30, 2026-0.46———
Nov 5, 2026Sep 30, 2026-0.44786-0.36+0.09+19.62%
Aug 5, 2026Jun 30, 2026-0.38717-0.49-0.10-26.56%
May 7, 2026Mar 31, 2026-0.44-0.38+0.06+13.64%
Mar 3, 2026Dec 31, 2025-0.42-0.48-0.06-14.29%
Nov 12, 2025Sep 30, 2025-0.43-0.32+0.11+25.58%

Upgrades / downgrades

ELVN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026GuggenheimreitBuyBuy
Oct 19, 2026HC Wainwright & Co.mainBuyBuy
Oct 2, 2026Morgan Stanleyinit—Overweight
Oct 1, 2026JP Morganinit—Overweight
Aug 18, 2026William Blairinit—Outperform
Aug 18, 2026Barclaysinit—Overweight

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ELVN — it syncs with the Stock Master app.

Insider holders

ELVN insider holders
InsiderRelationLatest transactionDateShares held
COLLINS HELEN LOUISEOfficerSaleOct 18, 202625,000
DERYNCK MIKA KDirectorSaleAug 3, 20260
GARLAND J SCOTTDirectorSaleSep 30, 20260
HEYMAN RICHARD ADirectorSaleFeb 16, 20260
HOHL BENJAMINChief Financial OfficerSaleOct 18, 202638,000
KINTZ SAMUELChief Executive OfficerSaleNov 16, 20250

Institution ownership

ELVN institution ownership
Holder% heldSharesValueReported
FMR, LLC14.71%10,827,727507.28MSep 29, 2026
Orbimed Advisors LLC.9.21%6,776,632317.49MSep 29, 2026
Polar Capital Holdings PLC8.73%6,425,271301.02MSep 29, 2026
Blackrock Inc.7.76%5,711,966267.61MSep 29, 2026
Commodore Capital Lp4.45%3,275,000153.43MSep 29, 2026
Vestal Point Capital, LP4.38%3,225,000151.09MSep 29, 2026

Fund ownership

ELVN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.56%1,883,37288.24MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.05%1,508,36470.67MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.74%1,280,00059.97MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund1.70%1,250,75458.60MAug 30, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.53%1,123,26352.62MSep 29, 2026
T. Rowe Price New Horizons Fund, Inc.1.10%807,32937.82MJun 29, 2026